Natalie S. Callander, MD, University of Washington Carbone Cancer Center
Articles
BCMA-Targeted Therapies in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
BELLINI Trial; Venetoclax-Vd in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Lenalidomide-Refractory Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Daratumumab With Carfilzomib in Frontline Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Management of Relapsed/Refractory Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Maintenance Therapy Approaches in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
MRD Monitoring in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
The Role of Transplant in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Treating Transplant-Eligible and -Ineligible MM
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Transplant-Ineligible Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Tolerability of Triplet Therapy in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Frontline Triplet Therapies in Multiple Myeloma
Keith Stewart, MB, CHB, UHN and Princess Margaret Hospital;Natalie S. Callander, MD, University of Washington Carbone Cancer Center ;Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center;Noopur Raje, MD, Massachusetts General Hospital;Peter Voorhees, MD, Atrium Health
July 17th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
